Abstract
No public abstract is available from the verified source records.
Yunn‐Fang Ho, Ming-Yen Lai, Hsiu‐Ying Yu, Da-Kong Huang, Wei-Cherng Hsueh, Tung-Hu Tsai, Chia-Chun Lin
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Influence of the route of administration on the area under the plasma concentration-time curve
10.1002/jps.2600580114 · 1969
Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs
10.1016/s0022-3565(25)28585-8 · 1970
Influence of first-pass effect on availability of drugs on oral administration
10.1002/jps.2600600909 · 1971
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
10.1016/s0169-409x(97)00039-2 · 1997
The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?
10.2165/00003088-200241040-00001 · 2002
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine
10.1016/0009-9236(95)90168-x · 1995
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
10.1016/s0009-9236(96)90177-0 · 1996
In vivo permeability studies in the gastrointestinal tract of humans
2003
Absorption of drugs from the rat small intestine
10.1016/s0022-3565(25)12018-1 · 1958
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Intestinal drug absorption and metabolism I: comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption
10.1002/jps.2600590204 · 1970
Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ
10.1002/jps.2600750203 · 1986
Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds
10.1023/a:1015927004752 · 1988
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability
10.1023/a:1016212804288 · 1995
Effects of ethanol on pharma-cokinetics and intestinal absorption of paraquat in animals
10.2131/jts.19.2_67 · 1994
The isolated perfused liver as a tool in drug metabolism studies
1999
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavie, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chro-matography
10.1016/s0378-4347(99)00079-1 · 1999
Simultaneous determinations of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography
10.1016/s0378-4347(00)00617-4 · 2001
Differential effects of hepatic microsomal enzyme inducing agents on liver blood flow
10.1016/0006-2952(78)90336-2 · 1978
Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
10.1016/s0090-9556(25)08414-4 · 1996
Drug absorption I: an in situ rat gut technique yielding realistic absorption rates
10.1002/jps.2600581006 · 1969
Reevaluation of the absorption of carbenoxolone using an in situ rat intestinal technique
10.1002/jps.2600790510 · 1990
Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation
10.1002/jps.2600750908 · 1986
First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference
10.1016/s0928-0987(01)00166-x · 2001
Effect of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats
10.1023/a:1011967519752 · 1998
Cytochrome P450 and vascular homeostasis
10.1161/hh2101.099268 · 2002
Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD
10.1183/09031936.01.18s320122 · 2001
Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung
10.1080/20024091064273 · 2002
Factors affecting the clinical development of cytochrome P450 3A substrates
10.2165/00003088-200342110-00003 · 2003
Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A
10.1016/s0006-2952(97)00100-7 · 1997
Oral absorption of the HIV protease inhibitors: a current update
10.1016/s0169-409x(99)00027-7 · 1999
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
10.1073/pnas.91.9.4096 · 1994
pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs
10.1016/s0090-9556(25)06651-6 · 1995
Pharmacoki-netic interactions between HIV-protease inhibitors in rats
10.1002/(sici)1099-081x(199907)20:5<241::aid-bdd182>3.0.co;2-u · 1999
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats
10.1211/0022357021778411 · 2002
Optimal per-fusion rate determined for in situ intestinal absorption studies in rats
10.1002/jps.2600700303 · 1981
Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes
10.1016/0378-5173(80)90140-4 · 1980
The liver as an organ
2006
Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans
10.1023/a:1016207525186 · 1995
No additional external references are available.